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1. INTRODUCTION 
 
 
 
Pituitary tumors are common intracranial neoplasms, accounting for 
up to 15% of intracranial tumors at surgery and 6-23% at autopsy 
(1). They include 20% of all primary brain and central nervous 
system tumors and represent the second most common type by 
histology in young-adults (20-34 years) according to the Central 
Brain Tumor Registry of the USA (2). Pituitary adenomas are 
generally associated with hormone overproduction and/or 
compression signs and symptoms due to the impingement of 
adjacent structures. For years, pituitary adenomas have been 
considered a rare clinical entity on the basis of population studies 
reporting a prevalence of 1:3571 – 1:5263 or even lower (3, 4). A 
meta-analysis based on autopsy and radiology series (5) reported a 
high prevalence of pituitary adenomas in unselected general 
population (16.7%). More recently, a population-based study in the 
province of Liège, Belgium, reported a 3-5 times higher prevalence 
of clinically relevant pituitary tumors (1:1064) then previously 
estimated (6). The vast majority of pituitary tumors are non-invasive, 
benign, slow–growing lesions (7), but some might require careful 
follow-up: local invasion is reported in up to 40% of surgically treated 
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pituitary adenomas (8, 9), resistance to medical treatment or 
recurrence leading to multi-modal therapy is not unusual (8), and the 
time between surgery and recurrence can be short because of a 
high proliferation rate (8,9). Such tumors may correspond to 
”atypical adenomas” as defined by the World Health Organization 
(WHO) classification (10), mainly characterized by invasive growth, 
elevated mitotic index, Ki-67 labelling index >3 % and extensive 
nuclear reactivity for p53 (10). Conversely carcinomas, accounting 
for <1% of all pituitary tumors, can result in distant metastases (11, 
12). Most are hormonally active tumors, mainly adrenocorticotropin 
(ACTH) and prolactin (PRL) secreting tumors. Prognosis is poor 
since both aggressive tumors and carcinomas commonly relapse 
after radical surgical excision with a scarce responsiveness to 
radiotherapy or chemotherapy, with specific target treatments being 
still lacking (9-12). Recent evidence has documented the successful 
use of temozolomide (TMZ), an alkylating chemotherapeutic agent, 
in the management of aggressive pituitary tumors and carcinomas 
(9, 13-27), with greater efficacy (up to 60%) being reported in 
aggressive PRL and ACTH-secreting pituitary tumors (9, 18).  
On the other hand, somatostatin receptors (SSTR), mainly subtypes 
SSTR2 and SSTR5, are abundantly expressed on pituitary tumor 
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cells. However, an appreciable proportion of tumors fail in 
responding to conventional somatostatin analogs (SA) despite 
expressing high levels of one or more SSTR. A series of 
mechanisms have been hypothesized to explain the resistance to 
SA treatment. Among them, the recently identified two novel 
truncated sstr5 variants, sst5TMD5 and sst5TMD4, absent in normal 
pituitary but expressed in pituitary tumors, have been shown to 
reduce ability of the conventional SA octreotide (OCT) at 
normalizing hormone secretion in poorly responsive tumors in vivo 
(28, 29), also suggesting the potential use of sst5TMD4 expression 
in surgically removed pituitary adenomas as a predictor of the 
subsequent response of different pituitary tumors to OCT therapy 
(28, 29). Recent in vitro studies have highlighted G protein-coupled 
receptor kinase (GRK) 2 and beta-arrestins as important players in 
driving SSTR desensitization and trafficking, with beta-arrestin 1 and 
GRK2 having a role in modulating GH secretion during SA treatment 
(30). The novel SA pasireotide (PAS) exhibits a high binding affinity 
for 4 out of 5 SSTR, mainly for SSTR2, SSTR3 and SSTR5 (31, 32). 
In primary cultures PAS potently suppresses GH, PRL and ACTH 
secretion (31, 32), and recent phase III clinical trials have 
demonstrated drug effectiveness in terms of hormonal excess 
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control and tumor shrinkage in patients with acromegaly and 
Cushing’s disease (33-35), raising the question of whether it may 
represent a promising therapy also aggressive pituitary tumors and 
carcinomas.  
More recently, the PI3K/Akt/mammalian target of rapamycin (mTOR) 
pathway has been proposed as a promising alternative target for 
treatment of aggressive pituitary tumors. The mTOR inhibitor 
everolimus (EVE) has been recently showed to exert an 
antineoplastic activity in several human neuroendocrine tumors, 
particularly when combined with SA (36-40). In vitro studies on both 
pituitary cell lines (41) and primary cultures (42, 43) have shown that 
EVE potently inhibits cell proliferation, reducing cell viability and 
promoting apoptosis, so suggesting that mTOR inhibitors might 
represent a promising alternative antiproliferative therapeutic option 
for pituitary aggressive tumors and carcinomas.  
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2. AGGRESSIVE PITUITARY TUMORS AND CARCINOMAS: 
CLASSIFICATION, DEFINITION AND EPIDEMIOLOGY 
 
2.1 Classification of pituitary tumors 
Pituitary adenomas are classified as microadenomas and 
macroadenomas by an arbitrary cutoff size of 10 mm, whereas 
tumors exceeding 40 mm in size are defined giant adenomas. Most 
of these tumors are noninvasive and benign in nature, and remain 
either within the sella or exhibit slow expansive growth onto 
surrounding tissues. A significant number of pituitary tumors, 25– 
55% depending on the criteria used, can show signs of invasion of 
dura, bone and/or surrounding anatomical structures (7, 44). 
However, these so-called “invasive” pituitary adenomas display 
benign behavior even in the presence of marked dural invasion and 
are not considered malignant by current definition. Truly malignant 
pituitary tumors (i.e., pituitary carcinomas) are only defined by the 
presence of cerebrospinal or systemic metastases and are 
exceedingly rare, with an incidence of <1% of symptomatic pituitary 
tumors (11, 12). The so-called “aggressive” adenomas lie between 
benign adenomas and malignant pituitary carcinomas and display a 
distinct clinical behavior with marked/gross invasion of nearby 
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anatomical structures, tendency towards resistance to conventional 
treatments and early postoperative recurrence. 
In 2004, the WHO published a classification system for pituitary 
tumors based upon immunohistochemistry distinguishing them 
according to the presence or absence of secretory products along 
with other ultrastructural features (Table 1) (10). Apart from benign 
typical adenomas and pituitary carcinomas, this classification also 
identified “atypical” adenomas as tumors with atypical morphological 
features suggestive of an aggressive behavior, substantiated further 
by the presence of invasive growth, high mitotic index, Ki-67 
labelling index >3%, as well as extensive nuclear staining for p53. 
This was the first attempt to identify pituitary tumors that have the 
potential to exhibit a distinctive course compared to benign 
adenomas, characterized by extensive growth and potentially 
malignant transformation (45, 46). However, this classification based 
on histopathological markers does not closely correlate with clinical 
behavior, as typical adenomas may occasionally exhibit early 
recurrence and resistance to therapy, whereas atypical adenomas 
are not always invasive, and they do not always exhibit recurrence. 
It is also acknowledged that atypical adenomas may share 
morphological and histological features with carcinomas, which are 
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distinctively characterized by cerebrospinal or distant metastases, 
poor prognosis and an overall fatal outcome. Therefore, the validity 
of the term “atypical adenoma” proposed by the 2004 WHO pituitary 
tumor classification system is now debatable, and tumors with a 
potential to display an aggressive clinical course need to be properly 
identified, introducing a new classification system incorporating 
novel molecular and genetic biomarkers that have recently been 
evaluated (47). 
 
2.2 Definition of pituitary tumor aggressiveness 
In contrast to the term “atypical adenomas” which was based on 
well-established proliferative and histological markers, the term 
“aggressive” pituitary tumor is not well-defined and is differently 
interpreted by individual clinicians. One aspect of aggressiveness is 
the invasive expansion into surrounding anatomical structures. The 
terms “aggressive” and “invasive” are often interchangeably and 
synonymously used in the literature; however, this is not always the 
case and creates considerable confusion as microscopic dura and 
cavernous sinus invasion and suprasellar expansion are commonly 
encountered in apparently benign adenomas (48). There is also 
great variation in the literature regarding the definition of 
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invasiveness based on imaging features, histological proof of 
sphenoid sinus mucosal invasion and/or intraoperative findings (49). 
Furthermore, the precise anatomical structure infiltrated is of 
importance since invasion of the clivus or sphenoid bone, as 
opposed to cavernous sinus invasion, is a more indicative feature of 
aggressive behavior (50). According to the Hardy’s classification, for 
example, only grade III (focal bone erosion) and grade IV (extensive 
bone erosion including skull base) tumors are considered invasive 
(Fig. 1) (51). Moreover, as far as parasellar invasion of the 
cavernous sinuses is concerned, only grade III and IV adenomas 
are considered truly invasive according to Knosp’s classification 
(Fig. 1) (52). 
Another feature of aggressiveness characterizing the behavior of 
such tumors is recurrence. Patients with apparently cured benign 
typical adenomas may develop recurrence of their tumors after 5–10 
years; however, early recurrence, within 6–12 months 
postoperatively, and the speed of tumor growth are more in favor of 
a tumor with aggressive behavior, although a definite time to tumor 
progression cutoff is yet to be established to distinguish these 
tumors from truly benign adenomas.  
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Additionally, patients with aggressive tumors usually exhibit 
resistance to conventional therapies, although early or late 
resistance to treatment may also occasionally occur in benign 
tumors, reflecting specific tumor receptor heterogeneity, 
tachyphylaxis and/or other unknown factors affecting drug efficacy.  
Aggressive pituitary tumors are thought to have a greater chance of 
giving rise to pituitary carcinomas with cerebrospinal or systemic 
metastases. Pituitary carcinomas develop with equal frequency in 
both sexes at a mean age of 44 years, with a latency period of 7 
years after the diagnosis of a pituitary tumor depending on tumor 
subtype (11, 12). Although de novo development of a malignant 
pituitary tumor cannot be excluded, in most case series pituitary 
carcinomas evolve from macroadenomas that exhibit invasive and 
proliferative features (53-55). This supports the view that pituitary 
carcinomas mainly arise from the transformation of initially benign 
adenomas that accumulate genetic aberrations over time exhibiting 
an aggressive behavior and eventually metastasizing (11, 12, 54, 
55). However, as not all aggressive tumors transform into 
carcinomas, it is important to develop tools to identify the subset of 
tumors at higher risk and to apply close clinical and radiological 
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surveillance along with all available treatments early in the course of 
the disease in an attempt to minimize their morbidity. 
 
2.3 Epidemiology of aggressive pituitary tumors and 
carcinomas 
Epidemiological characteristics of aggressive pituitary tumors have 
been poorly investigated. In fact, based on the WHO definition of 
atypical adenomas, only four independent retrospective studies 
have reported on the prevalence of such tumors (45, 56-58). 
Particularly, Saeger et al. (56) reported 12 atypical tumors out of 451 
total pituitary adenomas (2.7%) in the German Pituitary Tumor 
Registry. Scheithauer et al. (45) reported 6 atypical cases out of 78 
total pituitary adenomas (14.7%), with the prevalence of atypical 
cases being similar to that of 14.8% reported by Zada et al. (57). In 
a more recent single-center study, 13 out of 146 pituitary adenomas 
(8.9%) were atypical, and 38.4% of them developed recurrence (58). 
Overall, by combining the findings of these studies, aggressive 
tumors account for approximately 6% of all pituitary adenomas. 
There are no further studies describing similar epidemiological data 
on aggressive pituitary tumors. This is mainly ascribable to the lack 
of a standardized definition of aggressive tumors based not only on 
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histological or proliferative markers, but also on the clinical course 
and behavior. 
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3. MOLECULAR BASIS OF PITUITARY TUMOR 
AGGRESSIVENESS 
 
A cross-talk between fine deregulation of intracellular pathways and 
complex micro-environmental factors have been hypothesized to be 
implicated in pituitary tumor pathogenesis. The signaling pathways 
of growth, angiogenesis and hormone secretion are intricate, and 
alterations upon node molecules can lead to aberrant proliferation.  
 
3.1 Genetics  
Most pituitary tumors are sporadic, but in approximately 5% of cases 
they arise in a familial setting as a component of genetic syndromes 
such as the McCune–Albright syndrome (59), the multiple endocrine 
neoplasia type 1 (MEN 1) (60), the Carney Complex (61), the 
familial isolated pituitary tumor (FIPA) (62) and, more recently 
described, the MEN1-like phenotype, namely MEN 4 (63). Specific 
genes have been identified to predispose to pituitary tumorigenesis, 
including GNAS (59), MEN1 (60), PRKAR1A (61), AIP (64) and 
CDKN1B (63), but these are rarely involved in the pathogenesis of 
sporadic tumors. Very recently, a new genomic disorder, the X-
linked acrogigantism (X-LAG), has been described (65) as 
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characterized by early childhood-onset gigantism resulting from GH 
excess and caused by microduplication on X chromosome, including 
the GPR101 gene, that can be transmitted as a dominant trait (65).  
Such genetic alterations may predispose pituitary tumors to display 
an “aggressive” behavior. Particularly, in the context of MEN 1 
syndrome prolactinomas have been shown to be more aggressive 
than their sporadic counterparts (66, 67), although in a recent 
retrospective multicentre study (68) prolactinomas in patients with 
MEN1 have been found to respond well to medical treatment, and 
microadenomas to grow only occasionally and after many years 
without clinical consequences (68). AIP-mutated GH-secreting 
tumors have been demonstrated to occur at younger age, to be 
more invasive, to require more surgical interventions and to have 
lower decreases in GH and IGF-I levels and less tumor shrinkage 
while on SA (i.e., resistance to treatment with SA) as compared to 
AIP-non mutated somatotropinomas (69). Similarly, AIP-mutated 
prolactinomas have been found to occur generally in young males 
and to frequently require surgery or radiotherapy, as they are poor 
responsive or resistant to dopamine-agonists (DA) (69). 
Several other genetic alterations have been implicated in pituitary 
tumorigenesis, including the increased expression of pituitary tumor 
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transforming gene (PTTG). Changes in PTTG expression may relate 
to pituitary tumor angiogenesis, invasiveness and aggressiveness 
(70-72). PTTG expression has been found correlated with Ki-67 
expression in pituitary tumors (72). In addition, in hormone-secreting 
tumors, over-expression of PTTG has been reported to correlate 
with tumor invasiveness, since higher PTTG expression was 
observed in tumors that had invaded the sphenoid bone (stages III 
and IV) as compared with tumors that were confined to the pituitary 
fossa (stages I and II) (70).  
Other well-known tumor suppressor genes in other neoplasms, such 
as P53 and RB or common oncogenes, including those of the Ras-
family, are only rarely involved in the development of pituitary 
tumors (73-78). Particularly, a mutation of the H-Ras gene at codon 
12, Gly to Val, has been found in recurrent, highly invasive 
prolactinomas (74). A recent study showed the presence of P53 
gene mutations in pituitary carcinomas and confirmed their absence 
in pituitary adenomas (79). In carcinomas, a P53 gene mutation was 
additionally related to p53 protein over-expression in tumor cells, 
which may be diagnostically helpful (79). 
 
3.2 Cell cycle regulators 
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p21Cip1, p57Kip2, and p27Kip1, the Cip/Kip proteins members of the 
cyclin-kinase inhibitor family of proteins, directly inhibit the action of 
the cyclin E/ cdk2 complex in inducing progression from G1 into S 
phase in the cell cycle (80), and are therefore defined as cyclin-
dependent kinases inhibitors (CDKI). Epigenetic modulation of these 
genes, usually by promoter hypermethylation, result in CDKI under-
expression, that in turn may predispose to pituitary tumorigenesis 
(81-84). Particularly, in rat GH3 cell line p27Kip1 has been found 
under-expressed by promoter hypermethylation (81, 82). In humans, 
both p21Cip1 and p27Kip1 have been reported to be under-expressed 
at protein level in all types of pituitary tumors (83, 84). Importantly, 
p27Kip1 expression has been found inversely related to the mitotic 
index Ki-67, resulting much lower in pituitary invasive adenomas and 
carcinomas (85).  
Inappropriate methylation of CpG islands of other key cell cycle 
control and growth regulatory genes has been demonstrated. Such 
genes include the growth arrest and DNA damage-inducible protein 
gamma (GADD45G, 86), and death-associated protein kinase 
(DAPK, 87). GADD45G negatively regulates cell growth and is 
significantly under-expressed in GH-secreting and PRL-secreting 
pituitary tumors (88). The DAPK gene encodes for a calmodulin-
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dependent serine/threonine kinase, which positively mediates 
programmed cell death: loss of DAPK expression, in association 
with either CpG island methylation or homozygous deletion, 
preferentially segregates with pituitary tumors that show an invasive 
phenotype (87).  
 
3.3 Growth factors 
Fibroblast growth factors (FGF) and fibroblast growth factor 
receptors (FGFR) are known to be important for a variety of 
biological processes, including mitogenesis, differentiation, 
development, angiogenesis and tumorigenesis (89). FGF-2 has 
been shown to be over-expressed in pituitary tumor cells, with 
higher levels in more aggressive tumors (90). The expression of the 
pituitary tumor-derived FGFR-4 isoform (ptd-FGFR4), a 
constitutively phosphorylated protein with transforming properties in 
vitro and in vivo (91), has been found stronger in macroadenomas 
as compared to microadenomas, and correlated with cell 
proliferation assessed by Ki-67 (92). 
Angiogenesis is another essential process of solid tumors allowing 
their growth and determining tumor behaviour. Increased 
angiogenesis has been shown to be associated with the 
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development of metastases, poor prognosis, and reduced survival in 
several human tumors (93). However, the role of angiogenesis in the 
pituitary gland is yet to be completely clarified, since few studies 
have shown lower vascularisation in pituitary tumors compared with 
the normal gland, with discordant results (94-97). Moreover, the 
expression of VEGF and its receptor has been recently reported to 
differ between pituitary histological subtypes (98). VEGF expression 
has been found related to suprasellar extension, being more 
expressed on tumors with extrasellar growth than intrasellar ones 
(98), so suggesting the expression of VEGF and its receptor (VEGF-
R) as marker for poor outcome after partial tumor resection.  
 
3.4 Receptor modulation 
SSTR and dopamine receptors (DR) are abundantly expressed in 
pituitary normal and tumoral cells and have been highlighted as two 
critical regulators involved in the negative control of hormonal 
secretion and tumor shrinkage (99-105). SSTR and DR are Gai- 
protein coupled that inhibit adenylate cyclase activity and cAMP 
production and reduce intracellular calcium concentration and 
calcium flux oscillations. Upon receptor stimulation, somatostatin 
and the SA octreotide LAR (LAR), lanreotide (LAN), and PAS on 
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one hand, and dopamine and the DA bromocriptine and cabergoline 
on the other hand, suppress hormonal secretion from pituitary 
tumors (99-102). Moreover, SA and DA are known to induce tumor 
shrinkage of pituitary adenomas (103-105). 
The SSTR subtypes 1-5 are encoded by genes localized on different 
chromosomes (106-110). However, two forms of the SSTR2 
receptor, SSTR2A and SSTR2B, are generated via alternative 
splicing; these two isoforms only differ in the length of the 
cytoplasmic tail of the receptors (110).  
Several functional genetic aberrations associated with GH and IGF1 
changes have been described for SSTR5. LAR-resistant acromegaly 
has been described in a patient with a single germline mutation at 
Arg240Trp that attenuated somatostatin 28-inhibition of cAMP 
accumulation and MAPK pathway activation, as well as increased 
cell proliferation (111). SSTR5 single nucleotide polymorphisms 
(SNPs) at C1004T and T461C have been associated with GH and 
IGF-I levels (i.e., disease severity) in patients with acromegaly (112). 
SSTR5 SNP at the 663T allele has been reported associated with a 
younger age at diagnosis of acromegaly, increased body mass 
index, more frequent adenoma resection, and a lack of tumor 
shrinkage after SA therapy (113). 
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SSTR5 mRNA splice variant isoforms, namely sst5TMD5 and 
sst5TMD4, are truncated at the 5th or 4th transmembrane domain in 
a variety of pituitary tumors, but mostly in somatotroph adenomas 
(85% of tumors) (28). Particularly, sst5TMD4 expression has been 
shown to negatively correlate with ability of OCT or SST5- selective 
SA therapy to reduce GH levels (29), suggesting sst5TMD4 is a 
marker of resistance to SA (28, 29). sst5TMD4 mRNA and protein 
levels positively correlated with pituitary tumor invasiveness, and 
inversely with age or LAR inhibition of GH and IGF-I, so to confer 
aggressive features to somatotroph adenomas (114). Genetic 
SSTR5 aberration in somatotroph adenomas may contribute to 
tumor responsiveness to SA therapy and tumor growth, but the 
extent of this effect remains unclear. 
Beta-arrestins 1 and 2 and the G protein-coupled receptor kinase 
(GRK) 2, intracellular molecules involved in membrane receptor 
phosphorylation, desensitization, and trafficking, have been recently 
pointed out as a possible modulator of ligand activated-receptor 
response (30). Particularly, lower beta-arrestin 1 and higher GRK2 
mRNA expression have been shown to correlate with a greater GH 
suppression after treatment with OCT either in primary cultures of 
GH-secreting adenomas and in vivo (30). Similarly, beta-arrestin 1 
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and 2 mRNA have been found significantly lower in adenoma 
tissues from acromegalic patients who achieved IGF-I normalization 
and complete biochemical control after long-term treatment with SA 
(115). These findings suggest that beta-arrestins 1 GRK2 may play 
a role in modulating responsiveness to SA treatment. 
Five DR subtypes are encoded by five separate genes, D1DR to 
D5DR. However, as for SSTR, alternative splicing of dopamine 
receptor subtype 2 (D2DR) generates two variants: long (D2DRL) 
and short (D2DRS) (116). The coding sequences of D2DRS and 
DRD2L are similar, but the former lacks exon 5 (116).  
Filamin A (FLNA), a widely expressed large cytoskeleton protein, 
has been demonstrated to modulate responsiveness to medical 
treatment with DA in prolactinomas, as it plays a key role in D2DR 
signaling and cell surface expression (117). In primary cultures of 
PRL-secreting tumors, FLNA silencing in DA-responsive 
prolactinomas resulted in 60% reduction of D2DR expression and 
abrogation of DA-induced inhibition of prolactin release and 
antiproliferative signals, these results being replicated also in the 
MMQ cell line which endogenously express FLNA and D2R (117). 
On the other hand, FLNA overexpression in DA-resistant 
prolactinomas restored D2DR expression and prolactin 
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responsiveness to DA (117). These findings suggested that in 
prolactinomas resistance to DA may be related to the reduction of 
FLNA expression (117). More recently, FLNA has been 
demonstrated to be involved also in SSTR2 stabilization and 
signaling in both primary cultures of GH-secreting tumors and GH3 
cell lines, playing both a structural and scaffold functional role (118).  
 
3.5 Cell signaling pathways 
Abnormalities in cell signalling pathways are frequently seen in 
pituitary adenomas. Clarifying the role of the particular component 
involved in regulation of these pathways may represent potential 
selective targets for therapy, identifying the locus or loci of the 
initiating abnormalities. The serine–threonine kinases, including key 
mediators of tumorigenesis such as Raf, mitogen activated protein 
kinase (MAPK) cascades and Akt/protein kinase B, appear to be of 
interest.  
The PI3K/Akt/mTOR pathway is altered in many tumors (119), 
including pituitary adenomas (120). Phosphatidylinositol 3-kinase 
(PI3K) is activated as a result of the ligand-dependent activation of 
tyrosine kinase receptors, G-protein-coupled receptors or integrins. 
Receptor-independent activation of PI3K can also occur in cells 
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expressing a constitutively active Ras protein (121-123). The best-
characterised phosphorylation target of PI3K is Akt, also known as 
protein kinase B, resulting in the phosphorylation of a host of other 
proteins that affect cell growth, cell cycle entry and cell survival 
(124). Akt phosphorylation activates a serine–threonine kinase 
mTOR (mammalian target of rapamycin), which activates 40S 
ribosomal protein S6 kinase (p70S6K) and inactivates 4E-binding 
protein (4EBP1) (124). The tuberous sclerosis complex (TSC), 
which includes TSC1 and TSC2 and mediates between PI3K/Akt 
and mTOR, inhibits mTOR (125). Mitogenic stimuli activating Akt 
can directly phosphorylate TSC2, causing destabilisation of TSC2 
and inhibiting the formation of the TSC1/2 complex, leading to an 
increase of mTOR activity (125). 4E-BP1 inhibits the initiation of 
translation of mRNA for many factors, including c-myc and cyclin 
D1, through its association with eIF-4E (126, 127), and thus loss of 
the binding protein in response to mTOR activation will lead to 
enhanced proliferation. Akt is over-expressed (at both mRNA and 
protein levels) and over-activated (through phosphorylation) in all 
pituitary tumors, mainly non-functioning pituitary adenomas (NFA) 
(128). This up-regulation of Akt will increase the phosphorylation of 
p27Kip1, preventing its nuclear import and causing changes in the cell 
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cycle (128). Therefore, changes in the cell cycle occurring in 
pituitary adenomas may be secondary to activation of the Akt 
pathway (128). Noteworthy, constitutive activation of the TSC1/2 
complex, as occurs in tuberous sclerosis, appears to be associated 
with a risk of neuroendocrine tumorigenesis, especially insulinomas 
and ACTH-secreting pituitary tumors (129). 
The Raf/MEK/ERK pathway is a hierarchical cascade originating at 
the cell membrane with receptors for mitogens or growth factors, 
which recruit, via adapter proteins and exchange factors, the small 
guanosine triphosphatase Ras (119). Activated Ras in turn activates 
the serine–threonine kinase Raf (MAPKKK). Raf activates the 
mitogen-activated protein kinase kinase (MAPKK) MEK, which in 
turn phosphorylates and activates the mitogen-activated protein 
kinase (MAPK, or ERK1 and ERK2), which translocates to the 
nucleus and trans-activates transcription factors, changing gene 
expression to promote growth and mitosis (130). This MAPK 
pathway activation causes phosphorylation and activation of 
ribosomal S6 kinase and transcription factors such as c-myc, Elk1, 
c-Fos and cyclin D1 (131, 132), similar to the Akt/mTOR cascade, 
and resulting in the activation of genes associated with proliferation 
(133) and leading to cell transformation (134). Over-activation of Akt 
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may also lead to activation of the b-catenin pathway, which has 
been implicated in pituitary tumorigenesis (135). 
The most sensitive Raf, B-Raf, which is frequently mutated at the 
V600E position in melanomas and papillary thyroid cancer leading 
to constitutive activity, is not similarly mutated in sporadic pituitary 
adenomas, although it has been found over-expressed in pituitary 
adenomas, particularly NFA (136). MEK1/2 and its down-stream 
regulator ERK1/2 are also over-phosphorylated and hence over-
activated in all types of pituitary adenomas, compared to normal 
pituitary (137). Therefore, in pituitary adenomas both the 
Raf/MEK/ERK and PI3K/Akt/mTOR pathways are up-regulated in 
their initial cascade, implicating a pro-proliferative signal 
derangement upstream to their point of convergence (137). 
Raf/MEK/ERK and PI3K/Akt/mTOR pathways have been also 
shown to play an important role either in malignant transformation 
and in drug resistance in endocrine cancer cells, such as breast and 
prostate cancer cells (138). 
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4. TREATMENT FOR PITUITARY AGGRESSIVE TUMORS AND 
CARCINOMAS. 
 
Pituitary aggressive tumors and carcinomas are reportedly difficult to 
manage due to their size, invasiveness, rapid growth and high 
recurrence rate. Since clear-cut definition and reliable prognostic 
markers are lacking, such tumors are difficult to be identified at initial 
presentation, and therefore primary therapeutic approach is not 
different compared to other pituitary tumors, depending on the type 
of adenoma. Current therapeutic options include surgery, 
radiotherapy, and medical treatment. However, both aggressive 
tumors and carcinomas commonly relapse after radical surgical 
excision with a scarce responsiveness to radiotherapy or 
chemotherapy (9-12). The increasing evidence of the involvement of 
many molecular mechanisms in the pathogenesis of pituitary tumor 
aggressiveness or malignant transformation has raised the question 
of whether such pituitary tumors, similarly to other cancer types, 
may benefit from specific target therapies, which are drugs able to 
interfere with specific molecules involved in tumor cell growth and 
survival.  
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4.1 Surgery 
Surgery represents the primary treatment for pituitary adenomas, 
also including aggressive tumors and carcinomas (19). In fact, 
medical treatments are often ineffective in controlling hormonal 
hypersecretion and/or tumor growth in such tumors. Hence, (re-) 
surgery appears a feasible treatment option for aggressive and/or 
recurrent tumors, although remission rates after repeated 
transsphenoidal surgery are much lower (139-141). In cases where 
tumors extend significantly into the suprasellar region, the trans-
cranial approach may be advisable but the trans-sphenoidal or 
endoscopic approaches are also valid and can be used depending 
on the surgeon experience (50). Near-total surgical resection with no 
apparent remnant at postoperative imaging can be rarely achieved, 
as aggressive pituitary tumors tend to be infiltrative and recur over a 
relatively short time (27). Repeated pituitary tumor debulking 
surgeries can be performed to remove further emerging tumor tissue 
(142-144), albeit with less success, and increasing rate of 
complications such as worsened visual field, optic nerve palsy, 
meningitis, anterior pituitary deficiencies and diabetes insipidus (9), 
and can be combined with other therapeutic modalities such as 
systemic and/or radiological therapies to achieve tumor control (19). 
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4.2. Radiotherapy 
Radiotherapy is usually reserved as a third-line therapy (after 
surgery and medical therapy) or for a residual tumor that is not 
surgically resectable. Therefore, radiotherapy is a valuable adjuvant 
therapy for aggressive tumors that cannot be controlled by other 
treatment modalities, mainly to prevent tumor regrowth in 
incompletely excised adenomas. Conventional external radiotherapy 
(CER) is advised when the tumor size exceeds 30 mm or when 
histological examination reveals heavy infiltration into surrounding 
tissues, whereas stereotactic radiosurgery (SR) is the preferred type 
of postoperative radiation therapy when the lesion is well 
demarcated and does not impinge the optic chiasm (145). 
CER has been used in adjuvant settings to prevent tumor regrowth 
in large or partially removed pituitary tumors and for local control of 
expanding tumors, some of which were later proven to be 
aggressive pituitary tumors. CER efficacy ranges from 67 to 100% in 
several studies (145-147). CER has been shown to reduce 
recurrence of NFA remnants, particularly if administered 
immediately during the postoperative period (146), but its efficacy is 
often limited in aggressive tumors. However, after CER the most 
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common outcome is local tumor growth control, and only rarely 
tumor shrinkage has been reported (147).  
SR with delivery of high-dose radiation in a single visit or 
fractionated radiotherapy (smaller fractions of radiation given over a 
period of 4–6 weeks) can also be applied if the tumor is adjacent to 
radiation-sensitive normal tissues. Techniques such as Gamma-
Knife surgery, linear accelerator or Cyber-Knife can provide more 
precise targeting of the adenoma, offering better control of the dose 
of radiation received by adjacent structures, such as the pituitary 
stalk, pituitary gland, optic chiasm and cranial nerves in the 
cavernous sinus. Retrospective series with new SR methods have 
shown a similar efficacy as compared to CER (148, 149), with a 
tendency to achieve their effect slightly faster and with less frequent 
side effects, mainly pituitary deficiency (149).  
Regardless from the type of radiotherapy, the amount of radiations 
that can be administered is limited by the risk of optic neuropathy, 
necrosis in the temporal lobe and other brain areas and the rare 
possibility of developing a secondary brain tumor. There has been 
also concern about the possible role of radiotherapy in the 
transformation or progression of pituitary adenomas to carcinomas 
following the report of the sarcomatous change induced by 
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radiotherapy on a pituitary adenoma (150). However, this is unlikely 
to be a common consequence in view of the large number of 
irradiated pituitary tumors and the small number of pituitary 
carcinomas (151).  
 
 
4.3 Chemotherapy 
Aggressive pituitary adenomas have relatively low proliferation 
indices and seem to display certain aspects of well-differentiated 
tumors, thus poorly responding to standard chemotherapy (152). 
The same rule applies to pituitary carcinomas despite their relatively 
higher proliferation indices; however, due to the rarity of these 
tumors, no randomized prospective studies of systemic 
chemotherapy have been conducted. Different cytotoxic 
chemotherapy protocols including procarbazine-etoposide-lomustine 
(153) and lomustine-doxorubicin (154) have been used in patients 
with aggressive pituitary tumors, with no clinically relevant effects in 
terms of control of tumor growth and hormone secretion. In a small 
series of 7 patients, including 3 with aggressive pituitary tumors and 
4 with carcinomas, combination therapy with lomustine and 5-
fluorouracil showed an overall poor response rate in terms of tumor 
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shrinkage, although temporary clinical responses were noticed in 
some patients (152). Noteworthy, chemotherapy regimens only 
partly change survival rate in such patients. In fact, only a few 
patients have survived for longer than 1 year after chemotherapy 
(152, 155). However, most patients with pituitary carcinomas and 
distant metastases who were still alive at last follow-up had received 
some form of chemotherapy (152, 155-157). This observation, 
together with the apparent response to chemotherapy of some 
patients with aggressive tumors with either regression or 
stabilization of the disease, may justify the early use of 
chemotherapy in patients with recurrent highly aggressive and 
potentially malignant tumors who have already received maximum 
therapy with surgery and radiotherapy (152). However, the lack of 
randomized studies makes chemotherapy poorly defined in pituitary 
aggressive tumors and carcinomas. 
 
 
4.4 Medical treatment: role and perspectives of target therapies 
4.4.1 Temozolomide 
Since 2006, temozolomide (TMZ), originally approved for use in 
refractory glioblastoma multiforme, has been successfully used to 
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treat pituitary aggressive adenomas and carcinomas (13, 158-168). 
TMZ is an orally administered second generation alkylating agent, 
which exerts its action by attaching a methyl group to the O6 
position of guanine bases causing mispair with thymine bases, DNA 
damage, proliferation arrest and cellular apoptosis. O6-
methylguanine-DNA methyltransferase (MGMT) is a DNA repair 
enzyme that counteracts the effects of TMZ by removing alkylating 
adducts from DNA. TMZ can readily cross the blood-brain barrier, 
and its action is not cell cycle specific, meaning that it inhibits all 
stages of tumor cell growth, even in slow-growing tumors, such as 
pituitary tumors. Initial experience on the use of TMZ in pituitary 
aggressive tumors and carcinomas, mainly based on case reports or 
very small patient series, has documented an overall hormonal and 
tumoral response rate of approximately 69% in carcinomas and 60% 
in aggressive adenomas (13, 14, 17, 20). To date, eight 
independent studies have investigated the effects of TMZ in series 
including at least 5 patients with pituitary aggressive tumors or 
carcinomas (21, 23, 161-166). As shown in Table 2, combining data 
from these studies including overall 100 patients receiving 9-12 
cycles of therapy, TMZ induced a complete or partial response in 
42%, stabilization in 31% and progression in 31% (21, 23, 161-166). 
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Based on findings from re-operated patients, changes in 
histopathological and morphological features of tumors have been 
reported after TMZ treatment: tumor softening and friability have 
been noticed, making easier the resection at re-operation, and TMZ-
treated tumors exhibited fewer mitoses, lower Ki-67, hemorrhage, 
necrosis, and focal fibrosis (167, 168). The DNA repair enzyme 
MGMT reverses the methylation caused by TMZ, being the major 
mechanism of resistance to TMZ treatment. A significant inverse 
correlation has found between the response to TMZ and MGMT 
expression, evaluated by immunohistochemistry (9, 23, 161, 163); 
however, the absence of MGMT expression was not always 
predictive of tumor response (23, 161). Conversely, MGMT promoter 
methylation in pituitary tumors has been shown to have poor 
prognostic value since methylated MGMT promoter was found in a 
similar proportion of TMZ-sensitive tumors and TMZ-resistant 
tumors (9). A clinically relevant suggestion proposed by Raverot et 
al. (23) is that 3 cycles of TMZ identify treatment-responsive 
patients, whereas after 3 cycles of TMZ non-responders do not 
benefit from additional cycles. It is currently unclear which regimen 
offers the best efficacy and which is associated with a reduced risk 
of secondary malignancy, such leukemia or lymphoma (18), and 
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there are scant data to support whether TMZ can be used alone or 
in combination with other medications such as PAS or capecitabine 
(14, 169, 170). 
 
4.4.2 Pasireotide 
SA are the mainstay of medical treatment for pituitary adenomas. 
The second-generation SA PAS exhibits a high binding affinity for 4 
out of 5 SSTR, mainly for SSTR2, SSTR3 and SSTR5 (31, 32), and 
has been shown to exert antisecretory and antiproliferative effects 
on metastatic neuroendocrine tumors (NET) and pituitary adenomas 
(31-35, 171-180). Results of preclinical studies in NET have 
indicated PAS to reduce NET secretion and growth both in vitro and 
in vivo (173, 174), displaying an anti-proliferative activity higher than 
the first-generation SA OCT (175). In primary cultures of pituitary 
tumors PAS has been shown to potently suppress GH, PRL and 
ACTH secretion (31, 32), and cell viability (171). Recent phase III 
clinical trials have demonstrated PAS effectiveness in terms of 
hormonal excess control and tumor shrinkage in patients with 
acromegaly and Cushing’s disease (33-35). Responsiveness to PAS 
has been found to persist over time both in GH-secreting and ACTH-
secreting pituitary tumors (176-180). Moreover, in patients with 
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inadequately controlled acromegaly (35) PAS has been 
demonstrated to induce the achievement of complete disease 
control (i.e., GH and IGF-I normalization) in approximately 18% of 
cases after 24 weeks, as compared to none of the patients 
continuing treatment with first-generation SA LAR and LAN, 
suggesting that PAS provides superior efficacy compared with 
continued treatment with LAR or LAN, and could become the new 
standard pituitary-directed treatment in patients with acromegaly 
who are inadequately controlled by first generation SA (35). Such 
results, mainly in view of the effectiveness of PAS in resistant or 
poorly controlled acromegaly, have raised the question of whether it 
may represent a promising therapy also for pituitary aggressive 
tumors and carcinomas. A few reports have documented the 
efficacy of PAS in patients with pituitary aggressive tumors (165, 
181-183) in terms of control of both hormonal hypersecretion and 
tumor growth, whereas the escape to treatment following an initial 
excellent response to PAS has been reported in a patient with an 
ACTH-secreting pituitary carcinoma metastatic to bone (183).  
Some evidence also suggests the successful use of PAS in 
association to TMZ (170). Particularly, in a patient with ACTH-
secreting pituitary carcinoma and widespread intracranial, spinal and 
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systemic metastases, PAS addition to TMZ induced the 
improvement of patient clinical status, and a reduction of ACTH 
levels (170). After 12 months of combination therapy a sustained 
tumor control was achieved and persisted upon monotherapy with 
PAS for more than 9 months thereafter (170), suggesting that 
combined treatment with TMZ and PAS might be promising in 
patients with metastatic pituitary carcinomas. 
 
4.4.3 Everolimus 
The mTOR inhibitor EVE, originally approved for the treatment of 
breast and renal cell cancers, has been shown to exert an 
antineoplastic activity in several human neuroendocrine tumors, 
particularly when combined with SA (36-40). As for many tumor 
types, the PI3K/Akt/mTOR pathway has been demonstrated to be 
overexpressed and activated also in human pituitary adenomas 
(128, 184). Thus, pituitary tumors may be sensitive to the anti-
proliferative effects of mTOR inhibitors. In vitro studies on both 
pituitary cell lines (41) and primary cultures of pituitary tumors (42, 
43) showed that EVE potently inhibits cell proliferation, reducing cell 
viability and promoting apoptosis, thus suggesting that EVE might 
represent a promising alternative anti-proliferative therapeutic option 
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for pituitary aggressive tumors and carcinomas. However, the 
experience with the clinical use of EVE in patients harbouring such 
tumors is controversial, and the impact on patient survival appears 
the be scant. In fact, two reports have described the anti-tumoral 
effects of EVE in two patients with metastatic ACTH-secreting 
pituitary carcinomas (185, 186), including one resistant to TMZ 
(185). In this latter patient, EVE has been associated with LAR, but 
combined therapy failed to control pituitary tumor growth and ACTH 
secretion, and the patient died 3 months after treatment 
discontinuation (185). Conversely, the former patient received RT 
and EVE, leading to clinical improvement and stability on MRI and 
PET for >6 months (186). However, the patient expired from widely 
metastatic disease (186). 
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5. AIM 
 
To date, scant data are available about the epidemiological, clinical, 
radiological, and pathological characteristics, as well as about the 
molecular predictors of responsiveness to medical treatments, 
including the more recent target therapies, in patients with pituitary 
aggressive tumors and carcinomas.  
Therefore, the main objectives of the current study were: 
1. To investigate in vitro responsiveness to PAS and EVE, used 
as monotherapy or as combined treatment, in primary cultures 
of pituitary aggressive tumors.  
2. To assess the clinical, hormonal, radiological, and pathological 
characteristics in patients with pituitary aggressive tumors and 
carcinomas, evaluated both during the active disease and/or 
after the disease remission. 
3. To evaluate the incidence rates, tumor subtype, patho-
physiological mechanisms, clinical characteristics, and the 
therapeutic approaches performed. 
4. To allow a better standardization of the diagnosis and therapy 
of pituitary aggressive tumors and carcinomas. 
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6. PATIENTS AND METHODS 
 
6.1 In vitro study 
The in vitro study has included somatotroph tumors from patients 
undergoing trans-sphenoidal surgery at the Division of Neurosurgery 
at University “Federico II”, Naples. This study has been approved by 
the Ethics Committee of the University of “Federico II” of Naples, 
Italy, and informed consent has been obtained from each patient. A 
careful classification of patients on the basis of sex, age, histotype 
and tumor grade has been performed before pituitary samples 
collection. Experiments of the present study have been performed in 
primary cultures developed from surgically removed fresh tissue. 
Tissue samples have been placed in Hanks' balanced salt solution, 
supplemented with human serum albumin 5%, penicillin and 
streptomycin and fungizone, immediately after resection. The 
specimens have been first mechanically minced and then 
enzymatically dissociated with collagenase or dispase. Cells have 
been plated in multiwell plates in the appropriate growth medium 
and incubated at 37°C in a 5% CO2 humidified atmosphere. 
Twenty-one consecutive pituitary somatotroph tumors have been 
collected for the current study, including 5 aggressive somatotroph 
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tumors as defined on the basis of histopathological characteristics (4 
atypical tumors) or drug resistance (1 tumor), and 16 non-
aggressive tumors. Pathology study in all pituitary tumors has 
confirmed the GH phenotype by immunohistochemistry. Out of the 
total 21 tumors, 5 have been collected from patients who had 
received presurgical treatment with SA, DA or with the GH receptor 
antagonist pegvisomant (PEG). SSTR and mTOR pathway 
components in all 21 somatotroph tumors have been assessed in 
basal condition, whereas in 9 somatotroph tumors the effects of the 
SA OCT and PAS and of EVE on the modulation of receptor 
expression profile has been investigated. Drug effects on cell 
proliferation have been assessed by DNA assay in 9 non-aggressive 
somatotroph tumors and in all 5 aggressive somatotroph tumors. 
Drug effects on cell hormonal secretion have been assessed by 
CLIA assay in 5 non-aggressive somatotroph tumors and in all 5 
aggressive somatotroph tumors.  
 
 
6.1.1 Pharmacological compounds 
PAS has been kindly gifted by Novartis, whereas OCT, EVE and 
TMZ have been purchased by Selleck Chemicals. PAS and OCT 
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have been re-suspended in sterile water at concentration of 10-3M. 
EVE and TMZ have been re-suspended in DMSO 100% at 10-3M 
and 10-1M respectively. All drug stocks were stored at -80°C until 
using. Fresh serial dilutions in PBS 1X were made for PAS and OCT 
and in DMSO 10% for EVE and TMZ before starting each 
experiment.   
 
 
6.1.2 RNA isolation and RT-qPCR 
RT-qPCR was performed to quantify the messenger expression 
level of SSTRs, the most important mTOR pathway components 
(mTOR, 4eBP1 and p70S6K) and of IGF1R and IR (isoforms A and 
B). The cells were lysed on ice in a lysis binding buffer containing 
100 mM Tris-HCl (pH 8.0), 500 mM LiCl, 10 mM EDTA (pH 8.0), 1% 
LiDS, 5 mM DTT, and 5 Ltd., Cambridge, UK). The mRNA was 
isolated from total RNA with the use of prewashed Dynabeads Oligo 
beads were collected with a magnet and washed three times with 10 
mM Tris HCl (pH 8.0), 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS, and 
once with a similar buffer from which LiDS was omitted. The poly 
(A+) mRNA was eluted twice, for 2’ each time, in H2O (65°C) and 
20µl were used for cDNA synthesis in a Tris Buffer (50 mM Tris–HCl 
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(pH 8.3), 100 mM KCl, 4 mM DTT and 10 mM MgCl 2) with 10 units 
RNase inhibitor, 2 units avian myeloblastosis virus Super Reverse 
Transcriptase, oligo dT (5 ng/µl) and 1 mM of each dNTPs in a final 
volume of 40 µl. This mix was incubated for 1 h at 42˚C and the 
resulting cDNA was diluted fivefold in 160 µl sterile H2O. The cDNA 
was used for quantification of mRNA levels of all investigated genes. 
The total reaction volume (12 µl) consisted in 5 µl of cDNA, 0.5 µl of 
primers (1 μM) and 6.5 µl 1X Sybr Green Mix (Maxima SYBR Green 
qPCR Master Mixes, Thermo Fisher Scientific Inc. Waltham MA). 
Primers sequences and concentrations are shown in Table 3. All 
primers and probes were purchased from Sigma-Aldrich. RT-qPCR 
was performed with iCycler IQ5 (Bio-Rad Laboratories, CA, USA) 
and the reaction conditions were as follows: 95°C for 5 min, 40 
cycles at 95°C for 1 min, 60°C for 2 min, and 72° C for 1 min. 
Specific products were detected as clear single peaks at their 
melting curves. Values were normalized against the expression of 
the housekeeping gene β-actin. All samples were assayed in 
duplicate. The relative expression of target genes was calculated 
using the comparative threshold method, 2-ΔCt with efficiency 
correction of target and reference gene transcripts. To exclude 
genomic DNA contamination in RNA extracts, cDNA reactions were 
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also performed without reverse transcriptase and amplified with 
each primer pair. To exclude contamination of the PCR mixtures, 
reactions were also performed in the absence of cDNA template, in 
parallel with cDNA samples.  
 
 
6.1.3 Pharmacological study 
Tumoral somatotroph cells have been incubated in serum medium, 
containing D-valine to inhibit fibroblast growth while allowing 
selective growth of epithelial cells, with or without PAS10-8M, OCT 
10-8M, EVE 10-7M, and TMZ 10-4M for 4 days. Tumoral somatotroph 
cells have been also incubated with drug combinations of PAS plus 
EVE and OCT plus EVE in order to evaluate a potential drug 
additive effect. Each experimental condition has been assayed at 
least in triplicate wells. After 4 days, measurement of total DNA 
content, representative for the number of cells, has been performed 
using the bisbenzimide fluorescent dye (Hoechst 33258). 
Supernatants have been collected and frozen before measuring 
hormonal levels. Endogenous GH has been assayed using the 
Liaison hGH assay kit, based on a chemiluminescent method (CLIA) 
that uses monoclonal antibodies directed against the 22 kDa form of 
the GH peptide. The kit is calibrated against the NIBSC 98/574 
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International Standard (IS).  
 
6.2 In vivo study 
6.2.1 Study design 
This was an international, multicentre, retrospective, observational 
study. The study was officially endorsed by the European 
Neuroendocrine Association (ENEA). A dedicated database 
platform, called “Aggressive pituitary tumors: a Multicentre, 
Observational, Retrospective study of ENEA (A.M.O.R.E)”, was 
specifically created to collect retrospectively the data of patients with 
diagnosis of pituitary aggressive tumors and carcinomas, based on 
pathological (atypical and malignant tumors), clinical (tumor growth 
despite adequate treatment, disease recurrence, tumor 
invasiveness, resistance to conventional therapy) and/or radiological 
(giant tumors, distant metastasis) characteristics. The A.M.O.R.E 
platform was accessible online from across the world on the ENEA 
official website (http://www.eneassoc.org). All referral centers for 
pituitary aggressive tumors and carcinomas were invited to access 
the A.M.O.R.E platform to fill in data about clinical, hormonal, 
radiological, and pathological characteristics, as well as diagnostic 
and therapeutic approaches of patients with such tumors. Queries 
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for data clarifications were generated and sent to all partecipants 
starting from 24 months after the beginning of the study. Nowadays, 
the online A.M.O.R.E platform is still available and open for data 
collection, however for the purpose of the current study data 
collected until June the 30th 2016 were considered. 
 
6.2.2 Inclusion and exclusion criteria 
The study included patients with a diagnosis of pituitary aggressive 
tumors and pituitary carcinomas. Inclusion criteria were: 
- Patients with all type of pituitary tumors, including NFA, 
secreting pituitary adenomas (ACTH, GH, PRL, FSH, LH, 
TSH), and craniopharyngiomas  
- Age >18 yrs 
- Atypical pituitary adenoma (Ki-67 >3%, extensive p53 
immunoreactivity, increased mitotic activity) 
- Pituitary carcinoma 
- Disease recurrence 
- Tumor growth >20% in the last year despite medical therapy  
- Invasion of the surrounding structures  
- Deterioration of visual field or sudden visual loss 
- Resistance to conventional therapy  
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- Maximal tumor diameter >4 cm in adult (giant tumors)/ 2 cm in 
children/ 1 cm in ACTH secreting  
- Silent adenoma 
Exclusion Criteria were: 
- Responsiveness to conventional treatment 
- Meningiomas  
- Unavailability of clinical, biochemical, hormonal or radiological 
data 
 
6.2.3 Patients 
A total of 697 patients from 13 different countries (Italy no=185 
patients, Russia no= 138 patients, Bulgaria no=121 patients, Brazil 
no= 120 patients, Turkey no= 75 patients, Israel no= 33 patients, 
Austria no= 8 patients, Argentina no= 6 patients, Belgium no= 3 
patients, India no= 3 patients, Spain no=2 patients, Mexico no= 2 
patients, Canada no= 1 patient) received a diagnosis of pituitary 
aggressive tumors or carcinomas between 1979 and 2013. Sixty-
four patients were excluded from the study because of unavailability 
of clinical (no= 13 patients), hormonal (no= 8 patients), radiological 
(no=11 patients), pathological (no= 16 patients), diagnostic (no= 12 
patients) or therapeutic (no= 4 patients) data. Therefore, for the 
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purpose of the study 633 patients (237 females, 396 males, age at 
diagnosis 40.3±15.7 yrs) were considered for the final analysis. 
Patient profile at study entry is shown in Table 4. According to the 
classification system based upon histopathogical markers proposed 
by WHO (10) and to the presence of distant metastases (11, 12), 
tumors were classified as atypical, carcinomas, and non-atypical 
non-malignant. 
 
 
6.3 Statistical Analysis 
Data have been analyzed using SPSS Software for Windows, 
version 24.0 (SPSS, Inc., Cary, NC package). The comparison 
between the numerical data before and after treatment has been 
made by non parametric Wilcoxon test for two related samples, and 
by non parametric U Mann-Whitney or Student t test for not related 
samples with non normal and normal distribution, respectively. . The 
comparison between the numerical data among different groups of 
patients has been made by OnewayAnova for multiple comparisons 
corrected by Bonferroni exact test when necessary. The comparison 
between prevalence has been performed by χ2 test corrected by 
Fisher exact test when necessary. Significance has been set at 5%.  
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7. RESULTS 
 
 
7.1 In vitro study 
7.1.1 Characterization of SSTR, IGF1R, IRA, IRB and mTOR 
pathway components in human somatotroph tumors 
RT-qPCR analysis revealed that non-aggressive somatotroph tumor 
cells expressed slightly but not significantly higher levels of SSTRs 
and IGF1R compared with aggressive somatotroph tumor cells 
(Fig.2). No significant difference in mTOR components expression 
has been found between the two groups of somatotroph tumors. 
SSTRs, IGF1R, IRA, IRB and mTOR pathway components 
expression has been also evaluated in 9 somatotroph tumors, 
including 7 non-aggressive and 2 aggressive somatotroph tumors, 
after drug treatment. As shown in Fig. 3, PAS and EVE treatment 
did not induce gene transcription regulation even when combined 
after 1h of treatment, although a trend in increasing SSTR 
expression has been observed in non-aggressive somatotroph 
tumors after combined treatment.   
 
7.1.2 Functional study: DNA assay 
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Fig. 4 shows the effects of different treatments on cell proliferation. 
In 14 out of 21 somatotroph tumors, including 5 aggressive and 9 
non-aggressive tumors, cell proliferation has been tested after 4 
days of treatment. Incubation of cells from 9 non-aggressive 
somatotroph tumors with PAS 10-8M+EVE 10-7M in DMEM 
containing 10% FCS and D-Valine has significantly reduced cell 
proliferation by 30%. The same drugs, used alone, did not 
significantly change cell proliferation at tested doses. OCT, both 
used alone and in combination with EVE, has been tested on 5 non-
aggressive somatotroph tumors, with no significant effect on cell 
proliferation. In 5 aggressive somatotroph tumors, neither PAS, 
EVE, nor PAS+EVE have significanty inhibited cell proliferation at 
tested doses. In 2 non-aggressive somatotroph tumors and in 1 
aggressive somatotroph tumor TMZ did not significantly change cell 
proliferation at tested doses.  
 
7.1.3 Functional study: Hormonal assay 
Fig. 5 shows the effects of different treatment on GH secretion.  In 5 
non-aggressive somatostroph tumors, as compared to the control 
PAS, EVE and PAS+EVE significantly reduced GH secretion by 
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23,73% (p<0.01), 21% (p<0.05) and 28,96 % (p<0.001), 
respectively. In 2 non-aggressive somatotroph tumors OCT alone or 
combined with EVE did not significantly reduce GH secretion. In 5 
aggressive somatotroph tumors, PAS induced the significant GH 
secretion inhibition when used alone (27,28%, p<0.01) and 
combined with EVE (37%, p<0.0001 vs control, p<0.001 vs EVE 
alone). In non-aggressive somatotroph tumors TMZ did not 
significantly reduce GH secretion, and in aggressive somatotroph 
tumors it increased GH secretion (p<0.01) probably due GH 
excretion most likely because of its cytotoxic effect.  
 
7.2 In vivo study 
Clinical, hormonal and radiological characteristics of the whole 
cohort of patients with pituitary aggressive tumors and carcinomas 
are shown in Table 5. 
 
7.2.1 Whole patient cohort 
In the whole cohort, most patients (68.7%) were Caucasian. 
According to disease status, 50.1% of patients had active disease 
whereas 46.4% had achieved disease remission. Death had 
occurred in 22 patients (3.5%): causes of death included tumor 
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progression in 10 (45.4%), cerebrovascular accidents in 8 (36.4%), 
heart stroke in 3 (13.6%) and other malignancy in 1 (4.5%) (Fig. 6). 
Genetics had been assessed in 25% of patients and revealed 
isolated pituitary tumors in 85.5%, FIPA with AIP mutation in 4.4 %, 
FIPA with no AIP mutation in 8.8%, MEN1 syndrome in 0.6% and 
McCune Albright syndrome in 0.6%. Based on histopathological 
findings, 101 out of 633 patients (15.9%) had atypical pituitary 
tumors, whereas pituitary carcinomas were reported in 6 patients 
(0.9%). Non-atypical non-malignant tumors were described in 526 
patients (83.2%). In the whole cohort of 633 patients, distribution of 
pituitary tumor histotypes was as follows (Fig. 7): NFA= 27.6%; GH-
secreting tumors= 21.3%; GH and PRL-cosecreting tumors= 7.7%; 
PRL-secreting tumors= 20.8%; ACTH-secreting pituitary tumors= 
9%; craniopharyngiomas= 7.4%; FSH/LH-secreting pituitary tumors= 
5.8%. Approximately 5% of patients had a silent pituitary tumor. 
Overall, secreting and non-secreting tumors were found in 68.9% 
31.1% of patients, respectively. Microadenomas were reported in 
18.3% of cases, whereas the vast majority of patients (81.7%) 
harboured pituitary macroadenomas, including giant tumors in 
33.2%, tumors with maximal diameter > 2 cm in children in 3.3%, 
and ACTH-secreting tumors with maximal diameter > 1 cm in 5%. In 
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the whole patient cohort, maximal tumor diameter was 3.6±1.98 cm. 
Approximately 31% of patients had experienced tumor growth >20% 
in the last year despite medical therapy, whereas recurrence was 
reported in 15.3% of cases. Tumor invasiveness was the most 
commonly used criterion for tumor aggressiveness: bilateral or 
monolateral invasion of cavernous sinus was found in 35.2% and 
44.7% of patients, respectively; tumors grew up to the third ventricle 
or to the sellar floor in 25.9% and 34.3% of cases, respectively. 
Laterosellar extension was described in 67.3% of patients, whereas 
in 66.8% of cases suprasellar extension was reported. Overall, 3 or 
more clinical criteria for tumor aggressiveness (invasiveness, 
resistance to medical therapy, giant size and visual field defects) 
were found in 79% of patients. As a result of tumor invasiveness 
and extension, patients had headache in 46.3%, deterioration of 
visual field in 40.9%, sudden visual loss in 16.4%, intracranial 
hypertension in 10.4% and cerebrospinal fluid (CSF) leak in 4.6% of 
cases. The most frequent pituitary deficiency was hypogonadism 
(46.3%), followed by hypothyroidism (30.5%), GH deficiency 
(20.2%), hypocortisolism (19.3%), and diabetes insipidus (5%). 
Panhypopituitarism was described in 12.9% of cases. Resistance to 
conventional therapy was reported in 56.7% of patients, including 
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37.6% with resistance to DA bromocriptine and cabergoline, and 
19.1% with resistance to SA LAN, LAR and PAS. In the whole 
patient cohort, out of 767 total required surgical interventions 79.4% 
were performed with trans-sphenoidal approach, and 20.6% with 
transcranial technique. RT was required in 21.5% of patients, and 
was administered as CER in 61% and RS in 39% of cases, 
respectively. A second course of medical therapy was required in 
41.7% of patients, with 49.5% of patients receiving DA, 35.6% SA, 
7.5% the GH receptor antagonist pegvisomant, 4.3% the adrenal 
directed drug ketoconazole, and 0.3% TMZ. However, such 
treatment was unsuccessful in 81.6% of cases, as only 18.4% of 
patients achieved disease control.  
 
7.2.2 Atypical tumors 
Based on histopathological findings, 101 out of 633 total patients 
(15.9%, 48 females and 53 males, age at diagnosis 40.4±12.6 yrs) 
harboured an atypical pituitary tumor. According to disease status, 
52.5% of patients had active disease whereas 45.5% had achieved 
disease remission. Death had occurred in 2 patients (2%). 
Distribution of pituitary tumor histotypes was as follows: PRL-
secreting tumors= 34.6%; NFA= 30.7%; ACTH-secreting tumors= 
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14.8%; GH-secreting tumors= 14.8%; GH and PRL-cosecreting 
tumors= 2.9%; FSH/LH-secreting tumors= 1.9%. Approximately 5% 
of patients had a silent pituitary tumor. The vast majority of patients 
had macroadenomas (91%), including 23 giant adenomas (25%) 
and 9 ACTH-secreting tumors with maximal tumor diameter > 1 cm 
(9.8%). Maximal tumor diameter was 3.56±1.7 cm. Approximately 
20% of patients had experienced tumor growth >20% in the last year 
despite medical therapy, whereas recurrence was reported in 19% 
of cases. As far as tumor invasiveness is concerned, bilateral or 
monolateral invasion of cavernous sinus was found in 26.7% and 
38.6% of patients, respectively; tumors grew up to the third ventricle 
or to the sellar floor in 37.6% and 17.8% of cases, respectively. 
Laterosellar and suprasellar extension were both described in 
47.5% of patients. Overall, 3 or more clinical criteria for tumor 
aggressiveness (invasiveness, resistance to medical therapy, giant 
size and visual field defects) were found in 89% of patients. As a 
result of tumor invasiveness and extension, patients had headache 
in 47.5%, deterioration of visual field in 41.6%, sudden visual loss in 
16.8%, intracranial hypertension in 9.9% and CSF leak in 2% of 
cases. The most frequent pituitary deficiency was hypogonadism 
(33.6%), followed by hypothyroidism (24.7%), hypocortisolism 
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(22.7%), GH deficiency (12.9%), and diabetes insipidus (2%). 
Panhypopituitarism was described in 12.9% of cases. Resistance to 
conventional therapy was reported in 60.4% of patients, including 
44.5% with resistance to DA bromocriptine and cabergoline, and 
15.8% with resistance to SA LAN, LAR and PAS. In the cohort of 
patients with atypical adenomas, out of 80 total required surgical 
interventions 76.3% were performed with trans-sphenoidal 
approach, and 23.7% with transcranial technique. RT was required 
in 32.7% of patients, and was administered as CER in 75.8% and 
RS in 24.2% of cases, respectively. A second course of medical 
therapy was required in 60.7% of patients, with 49.1% of patients 
receiving DA, 40% SA, 9.9% the GH receptor antagonist 
pegvisomant, 6.3% the adrenal directed drug ketoconazole, an 1% 
TMZ. However, such treatment was unsuccessful in 86.3% of cases, 
as only 13.7% of patients achieved disease control.  
 
 
7.2.3 Carcinomas 
Six out of 633 total patients (0.9%, 1 female and 5 males, age at 
diagnosis 46±15.7 yrs) harboured a pituitary carcinoma. According 
to disease status, 50% of patients had active disease, and 50% had 
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died because of tumor progression and distant metastases. 
Distribution of pituitary tumor histotypes was as follows: ACTH-
secreting tumors= 66.6%; PRL-secreting tumors= 16.7%; NFA= 
16.7%. All patients had a pituitary macroadenoma (91%), including 
1 giant NFA (16.7%), 1 PRL-secreting tumors with maximal diameter 
> 2 cm in a child (16.7%) and 4 ACTH-secreting tumors with 
maximal diameter > 1 cm (66.6%). Maximal tumor diameter was 
3.5±1.5 cm. Tumor growth >20% in the last year despite medical 
therapy was reported in 33.3% of patients, and recurrence was 
found in 66.6%. As far as tumor invasiveness is concerned, bilateral 
or monolateral invasion of cavernous sinus was found in 33.3% and 
16.7% of patients, respectively; tumors grew up to the third ventricle 
or to the sellar floor in 66.6% and 33.3% of cases, respectively. 
Laterosellar and suprasellar extension were described in 66.6% and 
83.3% of patients, respectively. Overall, 3 or more clinical criteria for 
tumor aggressiveness (invasiveness, resistance to medical therapy, 
giant size and visual field defects) were found in 100% of patients. 
As a result of tumor invasiveness and extension, patients had 
headache in 83.3%, deterioration of visual field in 100%, sudden 
visual loss in 83.3%, intracranial hypertension in 33.3% and CSF 
leak in 16.7% of cases. The most frequent pituitary deficiency was 
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hypogonadism (83.3%), followed by GH deficiency (50%), 
hypothyroidism (33.3%), hypocortisolism (33.3%), and diabetes 
insipidus (33.3%). Panhypopituitarism was described in one third of 
cases. Resistance to conventional therapy was reported in 83.3% of 
patients, including 33.3% with resistance to DA bromocriptine and 
cabergoline, 33.3% with resistance to SA LAN, LAR and PAS, and 
16.7% with resistance to TMZ. In the cohort of patients with pituitary 
carcinomas, out of 7 total required surgical interventions 71.4% were 
performed with trans-sphenoidal approach, and 28.6% with 
transcranial technique. RT was required in two thirds of patients, 
and was administered as CER in 75% and RS in 25% of cases, 
respectively. A second course of medical therapy was required in all 
patients, with 83.3% of patients receiving DA and ketoconazole, and 
16.7% SA. However, such treatment was unsuccessful in 100% of 
cases, and no patient achieved disease control.  
 
 
7.2.4 Non-atypical non-malignant vs atypical and malignant tumors: 
comparison study 
Comparison between non-atypical non-malignant vs atypical tumors 
and carcinomas is shown in Table 5. 
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Active disease and disease remission were similarly described in 
both groups of patients, and no significant difference was found in 
mortality rate between patients with non-atypical non-malignant and 
those with atypical tumors and carcinomas. Histopathological 
distribution of pituitary tumors was different between the two groups, 
as PRL-secreting (p<0.001) and ACTH-secreting (p=0.002) tumors 
were significantly more prevalent in patients with atypical tumors 
and carcinomas as compared to those with non-atypical non-
malignant tumors. Prevalence of macroadenomas was significantly 
higher (p=0.021), and of microadenomas significantly lower 
(p=0.022) in patients with atypical tumors and carcinomas as 
compared to those with non-atypical non-malignant tumors. 
Similarly, prevalence of giant tumors (p=0.013) and of ACTH-
secreting tumor > 1 cm in size (p<0.001) was significantly greater in 
patients with atypical tumors and carcinomas as compared to those 
with non-atypical non-malignant tumors, whereas no significant 
difference was found in the rate of giant tumors in children between 
the two groups. Overall, maximal tumor diameter was significantly 
higher (p=0.001) in patients with atypical tumors and carcinomas as 
compared to those with non-atypical non-malignant tumors. As 
shown in Fig. 8, tumor growth (p=0.003) and disease recurrence 
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(p=0.05) were significantly more frequent in patients with atypical 
tumors and carcinomas as compared to those with non-atypical non-
malignant tumors; conversely, no significant difference was found 
between the two groups of patients in terms of tumor invasiveness, 
as bilateral or monolateral cavernous sinus invasion, and invasion of 
the third ventricle or of the sellar floor were similarly reported in both 
groups of patients. However, atypical tumors and carcinomas 
displayed a higher rate of laterosellar extension (p=0.05) compared 
to non-atypical non-malignant tumors, and a slight but not significant 
difference was found in the rate of suprasellar extension between 
the two groups of patients (Fig. 8). Thus, deterioration of visual field 
was significantly more prevalent in patients with atypical tumors and 
carcinomas as compared to those with non-atypical non-malignant 
tumors, whereas no significant difference was found in the 
prevalence of sudden visual loss, headache, intracranial 
hypertension and CSF leak. Such large and invasive tumors 
resulted in a similar prevalence of multiple or isolated pituitary 
hormone deficiency, including hypothyroidism, hypocortisolism, GH 
deficiency and diabetes insipidus, between the two groups of 
patients, with the only exception of hypogonadotropic hypogonadism 
that was significantly more frequent in patients with non-atypical 
Pituitary aggressive tumors and carcinomas: epidemiological, molecular, 
clinical, radiological, pathological and therapeutic characterization 
Renata S. Auriemma 
	 61 
non-malignant tumors as compared to those with atypical tumors 
and carcinomas. Both groups of patients were similarly resistant to 
medical therapy with SA, whereas the resistance rate to DA was 
found significantly higher in patients with atypical tumors and 
carcinomas as compared to those with non-atypical non-malignant 
tumors. As far as surgical therapy is concerned, the trans-
sphenoidal and the trans-cranial approaches were used in a similar 
proportion in both groups of patients. Conversely, radiotherapy was 
required in a significantly higher (p<0.001) proportion of patients 
with atypical tumors and carcinomas compared to those with non-
atypical non-malignant tumors; CER was administered more 
frequently (p<0.001) and RS more rarely (p<0.001) in presence of 
atypical tumors and carcinomas as compared to non-atypical non-
malignant tumors. Patients with atypical tumors and carcinomas 
required also more frequently (p<0.001) a second course of medical 
therapy, including either DA (p<0.001) and SA (p<0.001), as 
compared to patients with non-atypical non-malignant tumors. 
Disease control was achieved in a minority of patients in both 
groups, however unsuccessful treatment was more frequently 
reported in patients with atypical tumors and carcinomas as 
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compared to patients with non-atypical non-malignant tumors 
(p=0.042).  
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8. DISCUSSION 
 
The current in vitro study has first demonstrated that combined 
treatment with PAS and EVE is able to significantly inhibit cell 
proliferation and GH secretion in primary cultures of aggressive GH-
secreting pituitary tumors, thus suggesting the potential use of this 
therapeutic strategy as valid alternative treatment in patients with 
aggressive pituitary tumors poorly responsive to conventional 
medical treatments. Moreover, the current in vivo study has first 
demonstrated in a large cohort of patients with pituitary aggressive 
tumors that atypical tumors and carcinomas are larger, more 
recurrent and less responsive to medical treatment than non-atypical 
non-malignant pituitary adenomas, thus suggesting a greater 
biological and clinical aggressiveness of atypical tumors and 
carcinomas.  
In line with previous studies investigating in vitro the effects of the 
second generation SA PAS in patients with aggressive pituitary 
tumors (32, 171), the results of the current in vitro study have 
confirmed PAS to potently suppress GH secretion and to inhibit cell 
proliferation. Worth of note, this study has also highlighted the 
potential beneficial effects, mainly in terms of GH secretion, deriving 
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from the addition of EVE to PAS in patients with aggressive GH-
secreting tumors, besides the anti-proliferative effects induced by 
EVE in pituitary tumors already demonstrated in previous in vitro 
studies (41-43). Conversely, in the present study OCT and TMZ, 
nowadays considered the standard medical treatment for 
acromegaly and aggressive tumors, respectively, did not induce 
significant change in cell proliferation and GH secretion. However, 
such results may be explained, at least partly, considering that most 
experiments have been performed in few tumor samples, due to the 
rarity of pituitary aggressive tumors and carcinomas.  
Indeed, the current retrospective study has confirmed carcinomas to 
account for less than 1% of all pituitary tumors, in line with previous 
data (11, 12). Conversely, in the present patient cohort pituitary 
atypical tumors have been found in a slightly higher percentage of 
patients than previously reported, as they have been seen to 
account for approximately 16% of cases. Previous studies (45, 56-
58) have reported atypical pituitary tumors in 2.7%-14.8% of 
patients. However, these studies included much smaller patient 
series, as the largest included 146 patients (58), as compared to the 
present cohort. In fact, the current study is the first specifically 
investigating pituitary aggressive tumors, including atypical and 
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malignant ones, in a very large cohort of patients. Moreover, as the 
vast majority of patients of the current series have received the 
diagnosis of pituitary tumor between 1979 and 2009, before the 
availability of the classification system based on histopathological 
markers proposed by the WHO (10), we cannot exclude that the true 
prevalence of atypical tumors is still underestimated, and further 
investigations are needed to rule out definitive conclusions about the 
epidemiology of pituitary atypical tumors.  
In line with previous data (7, 44), the current study confirmed 
macroadenomas to represent the more prevalent tumor size in 
patients with aggressive tumors, either atypical, malignant and non-
atypical non-malignant. However, in the present cohort maximal 
tumor diameter was significantly larger in patients with atypical 
tumors and carcinomas as compared to those with non-atypical non-
malignant adenomas. Similarly, laterosellar extension was found to 
be more frequent in the former as compared to the latter. These 
findings were also confirmed by a higher prevalence of giant tumors, 
mainly those associated with ACTH-secretion, in patients with 
atypical tumors and carcinomas as compared to those with non-
atypical non-malignant tumors. However, characteristics of tumor 
invasiveness have been found to be similar in both groups of 
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patients, regardless from histopathological markers of 
aggressiveness. Indeed, no significant difference has been found in 
the prevalence of invasion of the cavernous sinus, third ventricle 
and sellar floor in the two groups of patients, whereas visual field 
defects were more frequent in patients with atypical tumors and 
carcinomas as compared to those with non-atypical non-malignant 
adenomas. These findings confirmed that invasive pituitary tumors 
are not always aggressive, and that in turn tumor aggressiveness is 
not always synonymous of invasiveness. Indeed, invasive pituitary 
adenomas often display benign behavior even in presence of 
marked dural invasion and are not considered malignant by current 
definition (187). Moreover, microscopic dura and cavernous sinus 
invasion, together with suprasellar expansion, are commonly 
encountered in non-atypical non-malignant (i.e., apparently benign) 
pituitary adenomas (48), and the invasion of the clivus or the 
sphenoidal bone is generally considered more indicative of 
aggressive behavior as opposed to the invasion of cavernous sinus 
(50). The current study first has shown laterosellar extension to be 
more prevalent in atypical tumors and carcinomas as compared to 
non-atypical non-malignant adenomas, suggesting that it might be 
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considered a distinctive radiological characteristic for atypical tumors 
and carcinomas.  
Other features of aggressiveness characterizing atypical tumors and 
carcinomas are speed of growth and recurrence. Even considering 
that typical and benign tumors can develop recurrence after a long 
latency (up to 10 years) postoperatively, early recurrence and fast 
tumor regrowth are more in favor of an aggressive behavior in 
atypical or malignant tumors (187). In line with this evidence, in the 
present study tumor growth and recurrence have been found to 
occur more frequently in atypical tumors and carcinomas as 
compared to non-atypical non-malignant adenomas.  
In line with previous literature (10, 18, 23, 158-170), the present 
study has confirmed that aggressive tumors, regardless from 
histopathological markers of aggressiveness, are generally 
associated with hormonal hypersecretion, mainly PRL and ACTH, as 
they have been found in nearly 70% of patients of the whole series. 
However, in both secreting and non-secreting tumors, 
responsiveness to medical treatment has been found scant. Indeed, 
in the whole patient cohort of the current study resistance to 
conventional medical treatments has been demonstrated in 
approximately 57% of patients, and in nearly 62% of those with 
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atypical tumors and carcinomas. Generally, in pituitary tumors 
resistance to conventional medical treatment is not a common 
finding, as pituitary adenomas usually display a good 
responsiveness to pituitary-directed drugs, mainly DA and SA. 
Particularly, resistance to DA has been reported to occur in 10% of 
microadenomas and 18% of macroadenomas in patients with 
prolactinomas (188), and escape to treatment is known to occur in 
up to 25% of patients with Cushing’s disease (104). In acromegaly, 
resistance to first-generation SA LAR and LAN has been 
demonstrated in approximately 25% of patients (189). No data are 
nowadays available about the resistance to the second-generation 
SA PAS, as it has been commercialized very recently for the 
treatment of patients with Cushing’s disease and acromegaly. In 
typical and benign pituitary adenomas, early or late resistance to 
medical treatments may occasionally occur, mainly because of 
specific tumor receptor eterogeneity, tachyphylaxis or other factors 
influencing drug effectiveness, such as the expression of receptor 
isoforms (110, 116) or truncated variants (28, 29, 114), functional 
aberrations (111-113), and/or receptor interaction with specific 
receptor modulators (30, 115, 117, 118). In the present study 
resistance to DA and SA, used either before and/or after surgery 
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and radiotherapy, has been shown to occur more frequently in 
patients with atypical tumors and carcinomas as compared to those 
with non-atypical non-malignant tumors. As for the limitations of a 
retrospective study, no data were available about DR and SSTR 
expression in the current patient series, however alterations in 
receptor expression or function cannot be excluded. Indeed, the in 
vitro study has shown that in aggressive somatotroph tumors SSTR 
expression was lower, although not significantly, than that found in 
non-aggressive tumors.  
Among patients resistant to conventional medical treatments, only 
two received TMZ (one with atypical tumor and one with non-
atypical non-malignant adenoma) and only 4 were treated with PAS 
(all with non-atypical non-malignant tumors). This can be explained 
taking into account that both compounds have been officially 
approved only very recently for the treatment of aggressive pituitary 
tumors (TMZ), and for Cushing’s disease and acromegaly refractory 
to first-generation SA (PAS). However, in previous studies TMZ has 
been successfully used to treat pituitary aggressive adenomas and 
carcinomas (13, 21, 23, 158-168), inducing complete or partial 
response in 42%, stabilization in 31% and progression in 31% of 
patients (21, 23, 161-166). Similarly, a few studies have 
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documented the efficacy of PAS in patients with pituitary aggressive 
tumors (165, 181-183) in terms of control of both hormonal 
hypersecretion and tumor growth, although the escape to treatment 
following an initial excellent response to PAS has been reported in a 
patient (183). Noteworthy, none of the patients of the current series 
received EVE. This finding is not surprising, as EVE is officially 
approved for the treatment of gastroenteropancreatic NET, besides 
breast and renal cell cancers, but not for pituitary tumors. However, 
the in vitro study has shown that EVE addition to PAS significantly 
reduced GH secretion in patients with aggressive GH-secreting 
tumors, besides the anti-proliferative effects already documented in 
previous in vitro studies (41-43). These findings can be explained 
taking into account that SA inhibit PI3K/Akt signalling upstream of 
mTOR, suggesting that the combination of a SA and a mTOR 
inhibitor, such as PAS and EVE, may have greater efficacy than 
either as single agents (190). Clinical trial experience has provided 
some encouraging findings and prompted the design of additional 
studies of this dual-targeted approach to treating advanced NET 
(36-39). 
As a result of such poor responsiveness to conventional medical 
treatment and the unavailability of new target therapies, most 
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patients have received more than one surgery followed by radiation 
therapy. Particularly, patients with atypical tumors and carcinomas 
required RT more frequently than those with non-atypical non-
malignant tumors. Worth of note, in the former CER was more 
commonly used as compared to RS, most likely because of the 
large tumor size (145). 
However, despite this multimodal therapeutic approach, disease 
control has been shown to be rarely achieved in patients with 
aggressive tumors of the current cohort. Control has been found to 
occur in approximately 18% of patients in the whole series, in nearly 
14% of atypical tumors and in none of patients with pituitary 
carcinomas. In the vast majority of patients, the multimodal 
treatment has failed to induce disease control, and persistent 
disease has been found in 82% of patients in the whole cohort, 86% 
of those with atypical tumors and 100% of those with pituitary 
carcinomas.  
Altogether, the results of the current study appear to suggest that 
the early identification of patients with aggressive tumors, either 
atypical, malignant or non-atypical non-malignant, is mandatory to 
apply close clinical and radiological surveillance along with all 
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available treatments early in the course of the disease in an attempt 
to increase the cure rate and to minimize their morbidity. 
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9. CONCLUSIONS 
Knowledge about epidemiological, clinical, molecular and 
pathological characteristics of pituitary aggressive tumors and 
carcinomas is still scant, and strong evidence about the best 
therapeutic approach is yet to be achieved. The current study has 
confirmed pituitary carcinomas to be exceptionally rare, but 
highlighted that atypical tumors might be more common than 
previously thought. Apart from the clear cut definition of atypical and 
malignant pituitary tumors, based on WHO criteria and on the 
presence of distant metastases, respectively, nowadays tumors 
size, recurrence, laterosellar extension and responsiveness to 
conventional medical treatments appear to be the best clinical and 
radiological criteria to discriminate pituitary tumors with a true 
aggressive behavior. Conversely, tumor invasiveness is not a good 
predictor of tumor aggressiveness and cannot discriminate pituitary 
atypical and malignant tumors from typical and benign adenomas. 
Radiotherapy and medical treatments remain the most commonly 
used therapeutic approaches for pituitary aggressive tumors, but fail 
to induce the achievement of disease control in most patients. In 
vivo experience with new target therapies, such as PAS and EVE, is 
still scant, however in vitro data support the use of combined 
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treatment with PAS and EVE as potential valid alternative treatment 
in patients with aggressive pituitary tumors poorly responsive to 
conventional medical treatments. Drug responsiveness can be, 
however, influenced by specific tumor receptor eterogeneity, 
tachyphylaxis or other factors influencing drug effectiveness, such 
as SSTR and mTOR components expression profile, and in turn 
early identification of molecular markers able to predict 
responsiveness to treatment might drive endocrinologists through 
the choice of the best individualized adjuvant therapy in patients 
with pituitary aggressive tumors and carcinomas. Further studies are 
needed to better elucidate the burden and the role of new target 
therapeutic strategies, such as PAS and EVE, on the tumor growth 
and hormonal hypersecretion in patients with pituitary aggressive 
tumors and carcinomas.    
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Table 1: Classification of pituitary tumors according to the WHO 
 
 
PRL-secreting adenoma (lactotroph adenoma or prolactinoma) 
 Densely granulated 
 Sparsely granulated 
  
GH-secreting adenoma (somatotroph adenoma) 
Monohormonal Densely granulated 
 Sparsely granulated 
Plurihormonal Mixed GH-PRL 
 Mammosomatothoph 
 Acidophilic stem cell 
  
ACTH-secreting adenoma (corticotroph adenoma) 
 Densely granulated 
 Sparsely granulated 
 Silent corticotroph subtype 1 and 2 
  
TSH-secreting adenoma (thyrotroph adenoma) 
 Densely granulated 
 Sparsely granulated 
  
FSH/LH adenoma (gonadotroph adenoma or non-functioning adenoma-NFA) 
  
Null-cell adenoma (oncocytoma) 
  
Various Silent subtype 3 tumor 
 Plurihormonal 
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Table 2: Response to temozolomide in patients with pituitary 
aggressive tumors and carcinomas 
 
Reference Author, yr Patient No Cycle No Response Stabilization Progression 
21 Losa, 2010 6 12 2/6 2/6 2/6 
23 Raverot, 2010 8 9 3/8 - 5/8 
161 Bush, 2010 7 9 2/7 4/7 1/7 
162 Hiroata, 2013 13 12 9/13 2/13 2/13 
163 Bengtsson, 2015 24 10 11/24 4/24 9/24 
164 Bruno, 2015 6 9 2/6 - 4/6 
165 Ceccato, 2015 5 11 2/5 1/5 2/5 
166 Losa, 2016 31 Up to 12 11/31 14/31 6/31 
 TOTAL 100  
42/100 
42% 
27/86 
31% 
31/100 
31% 
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Table 3: Primers sequences and concentrations used in the current 
study. 
 
 
Gene Primer Efficiency 
SSTR1 
Forward: 5’ – TGAGTCAGCTGTCGGTCATC – 3’ 
Reverse: 5’ – ACACTGTAGGCACGGCTCTT – 3’ 
1.81 
SSTR2 
Forward: 5’ – TCGGCCAAGTGGAGGAGAC – 3’ 
Reverse: 5’ – AGAAGACTCCCCACACAGCCA – 3’ 
1.86 
SSTR3 
Forwrd: 5’ – CTGGGTAACTCGCTGGTCATCTA – 3’ 
Reverse: 5’ – AGCGCCAGGTTGAGGATGTA – 3’ 
1.9 
SSTR5 
Forward: 5’- CATCCTCTCCTACGCCACACG – 3’ 
Reverse: 5’ – GGAAGCTCTGGCGGAAGTT – 3’  
2 
DRD2 
Forward: 5’- CAAGACCATGAGCCGTAGGAA – 3’ 
Reverse: 5’ – CGGGATGTTGCAGTCACAGT – 3’ 
2 
mTOR 
Forward: 5’- TGCTGCGTGTCTTCATGCAT- 3’ 
Reverse: 5’- GGATTGCAGCCAGTAACTTGATAG - 3’ 
2 
p70 
Forward: 5’- TGGAAGACACTGCCTGCTTTT – 3’ 
Reverse: 5’ – TGATCCCCTTTTGATGTAAATGC- 3’ 
2 
4EBP1 
Forward: 5’ – GGCGGCACGCTCTTCA – 3’ 
Reverse: 5’ -  TCAGGAATTTCCGGTCATAGATG – 3’ 
1.8 
IGF1R 
Forward: 5’ -  CCAAAACTGAAGCCGAGAAG – 3’ 
Reverse: 5’ – GGGTCGGTGATGTTGTAGGT – 3’ 
2 
IRA 
Forward:  5’ – CGTTTGAGGATTACCTGCACAA – 3’ 
Reverse: 5’ – GCCAAGGGACCTGCGTTT – 3’ 
2 
IRB 
Forward: 5’ – CCCAGAAAAACCTCTTCAGGC – 3’ 
Reverse: 5’ – GGACCTGCGTTTCCGAGA – 3’ 
2 
β-Actin 
Forward: 5’ – TCCTCCTGGGCATGGAG – 3’ 
Reverse: 5’ – AGGAGGAGCAATGATCTTGATCTT – 3’ 
1.7 
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Table 4: Patient profile at study entry  
 
Patient number 633 
Male/Female 396/237 
Age at diagnosis 40.3±15.7 
Non-secreting tumors 197 (31.1%) 
Secreting tumors  436 (68.9%) 
PRL-secreting adenomas 218 (34.4%) 
GH-secreting adenomas 118 (18.6%) 
GH silent 4 (0.6%) 
GH and PRL-cosecreting adenomas 34 (5.4%) 
ACTH-secreting adenomas 40 (6.3%) 
ACTH silent 5 (0.8%) 
TSH-secreting adenomas 3 (0.5%) 
FSH/LH-secreting adenomas 21 (3.3%) 
NFA 152 (24%) 
Craniopharyngiomas 32 (5%) 
Carcinomas 6 (0.9%) 
 
Abbreviations: NFA= non-functioning pituitary adenomas 
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Table 5: comparison of non-atypical non-malignant versus atypical 
tumors and carcinomas. 
 
 
 Non-atypical 
Non-malignant 
Atypical and 
malignant 
P 
Active disease (%) 56.3 52.3 0.51 
Disease remission (%) 43.7 42.9 0.96 
Deaths (%) 3.2 4.7 0.63 
PRL-secreting (%) 16.1 33.6 <0.001 
GH-secreting (%) 22.8 14 0.06 
ACTH-secreting (%) 7.2 17.7 0.002 
NFA (%) 27.2 29.9 0.42 
Silent tumors (%) 5.1 4.7 0.94 
Macroadenomas (%) 79.6 89.7 0.021 
Microdenomas (%) 20.3 10.3 0.022 
Giant tumors (%) 22.4 35.4 0.013 
ACTH-secreting tumor > 1 cm (%) 3.4 12,1 <0.001 
Tumor >2 cm in children (%) 3.8 1  
Maximal tumor diameter (cm) 2.97±1.68 3.7±2.0 0.0001 
Tumor growth (%) 20.6 36.3 0.003 
Disease recurrence (%) 14.1 21.5 0.05 
Tumor invasiveness    
        Cavernous sinus-bilateral (%) 36.9 38.3 0.07 
        Cavernous sinus-monolateral (%) 46.2 36.4 0.08 
        Third ventricle (%) 27 20.5 0.20 
        Sellar floor (%) 33.8 36.4 0.69 
Extension-laterosellar (%) 38.2 48.6 0.04 
Extension-suprasellar (%) 65.6 72.9 0.09 
Headache (%) 45.6 49.5 0.53 
Visual field deterioration (%) 39.9 45.8 0.03 
Sudden visual loss (%) 15.6 20.5 0.27 
Intracranial hypertension (%) 10.3 11.2 0.92 
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CSF leak (%) 4.9 2.3 0.35 
Hypopituitarism    
        Hypogonadism (%) 48.3 36.5 0.03 
        Hypothyroidism (%) 31.5 25.2 0.24 
        Hypocortisolism (%) 18.4 23.4 0.29 
        GH deficiency (%) 21.3 15 0.18 
        Diabetes insipidus (%) 5.3 3.7 0.65 
        Panhypopituitarism (%) 12.7 14 0.84 
Resistance to medical therapy (%) 55.7 61.7 0.30 
        DA (%) 36.5 69.7 <0.001 
        SA (%) 19.6 27.3 0.98 
Surgery    
        Trans-sphenoidal (%) 79.8 75.9 0.43 
        Trans-cranial (%) 20.1 24.1 0.44 
Radiotherapy (%) 18.8 34.6 <0.001 
        CER (%) 55.5 75.7 <0.001 
        RS (%) 44.5 24.3 <0.001 
Second course pharmacotherapy (%) 37.4 62.6 <0.001 
        DA (%) 48.7 83.6 <0.001 
        SA (%) 35.5 61.2 <0.001 
Disease control (%) 21.5 13.1 0.05 
No disease control (%) 78.5 86.9 0.04 
 
Abbreviations: NFA= non-functioning pituitary adenomas; CSF= cerebrospinal fluid; DA= 
dopamine-agonists; SA= somatostatin analogs; CER= conventional external ratiotherapy; 
RS= radiosurgery.  
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LEGEND TO FIGURES 
Figure 1: Hardy’s (left) and Knosp’s (righ) classification of pituitary 
tumor invasiveness. In Hardy’s classification, upper panel shows the 
classification of sphenoid bone invasion: grade 0= intact with normal 
contour; grade I= intact with bulging floor; grade II= intact, with 
enlarged fossa; grade III= localized sellar destruction; grade IV: 
diffuse destruction. Only grade III and IV tumors are considered 
invasive. Lower panel depicts a classification of the suprasellar 
extension of an adenoma which may be symmetrical or 
asymmetrical: grade A= suprasellar cistern only; grade B= recess of 
the third ventricle; grade C= whole anterior third ventricle; grade D= 
intracranial extradural; grade E= extracranial extradural (cavernous 
sinus).  According to Knosp’s classification, Grade 0= the adenoma 
does not pass the tangent of the medial aspects of the internal 
carotid artery (ICA); grade I= the medial tangent is passed, but the 
extension does not go beyond the intercarotid line, which is the line 
drawn between the cross-sectional centers of the intra- and 
supracavernous ICA; Grade II= the tumor is extending beyond the 
intercarotid line, but not beyond or tangent to the lateral aspects of 
the intra- and supracavernous ICA; Grade III = the tumor is 
extending laterally to the lateral tangent of the intra- and 
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supracavernous ICA; Grade IV= total encasement of the 
intracavernous carotid artery. Adapted from references 51 and 52.  
 
Figure 2: Characterization of SSTRs, IGF1R, IRA, IRB and mTOR 
pathway components in human somatotroph tumors. RT-qPCR 
analysis revealed that non-aggressive somatotroph tumor cells 
expressed slightly but non significantly higher levels of SSTRs 
(Panel A) and IGF1R (Panel B) compared with aggressive 
somatotroph tumor cells. No significant difference in mTOR 
components expression has been found between the two groups of 
somatotroph tumors (Panel C). 
 
Figure 3: Effects of PAS, EVE and PAS+EVE on SSTR gene 
transcription regulation in non-aggressive (Panel A) and aggressive 
(Panel B) somatotroph tumors. PAS+EVE did not induce gene 
trascription regulation after 1h of treatment, although a trend in 
increasing SSTR expression has been observed in non-aggressive 
somatotroph tumors (Panel A).  
 
Figure 4: Figure 4: Effects of different treatments on cell 
proliferation. In non-aggressive somatotroph tumors, only PAS 10-
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8M+EVE 10-7M significantly reduced cell proliferation by 30%, 
whereas thee same drugs used alone did not significantly change 
cell proliferation at tested doses (Panel A). OCT, both used alone 
and in combination with EVE, did not significantly change cell 
proliferation at tested doses (Panel B). In 5 aggressive somatotroph 
tumors, neither PAS, EVE, nor PAS+EVE significanty inhibited cell 
proliferation at tested doses (Panel C). In 2 non-aggressive 
somatotroph tumors and in 1 aggressive somatotroph tumor TMZ 
did not significantly change cell proliferation at tested doses (Panel 
D). 
 
Figure 5: Effects of different treatments on GH secretion. In 5 non-
aggressive somatostroph tumors, as compared to the control PAS, 
EVE and PAS+EVE significantly reduced GH secretion by 23,73% 
(p<0.01), 21% (p<0.05) and 28,96 % (p<0.001), respectively (Panel 
A). In 2 non-aggressive somatotroph tumors OCT alone or 
combined with EVE did not significantly reduce GH secretion (Panel 
B). In 5 aggressive somatotroph tumors, PAS induced the significant 
GH secretion inhibition when used alone (27,28%, p<0.01) and 
combined with EVE (37%, p<0.0001 vs control, p<0.001 vs EVE 
alone) (Panel C). In non-aggressive somatotroph tumors TMZ did 
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not significantly reduce GH secretion, and in aggressive 
somatotroph tumors it increased GH secretion (p<0.01) probably 
due GH excretion most likely because of its cytotoxic effect (Panel 
D).  
 
Figure 6: Mortality in the whole cohort of patients with pituitary 
aggressive tumors and carcinomas. Causes of death included tumor 
progression (TP) in 10 (45.4%), cerebrovascular accidents (CVA) in 
8 (36.4%), heart stroke (HS) in 3 (13.6%) and other malignancy in 1 
(4.5%).  
 
Figure 7: Distribution of pituitary tumor histotypes. NFA= 27.6%; 
GH-secreting tumors= 21.3%; GH and PRL-cosecreting tumors= 
7.7%; PRL-secreting tumors= 20.8%; ACTH-secreting pituitary 
tumors= 9%; craniopharyngiomas (CP)= 7.4%; FSH/LH-secreting 
pituitary tumors= 5.8%.  
 
Figure 8: Comparison of non-atypical non-malignant tumors versus 
atypical tumors and carcinomas. Rate of tumor growth (p=0.003), 
disease recurrence (p=0.05), and laterosellar extension was 
significantly higher in patients with atypical tumors and carcinomas 
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as compared to those with non-atypical non-malignant tumors. 
Invasion of cavernous sinus, third ventricle and sellar floor, and 
suprasellar extension were similarly reported in both groups of 
patients.  
 
Knosp’s classificationHardy’s classification
Figure 1: Hardy’s (left) and Knosp’s (righ) classification of pituitary tumor invasiveness. In Hardy’s classification, upper panel shows the classification of
sphenoid bone invasion: grade 0= intact with normal contour; grade I= intact with bulging floor; grade II= intact, with enlarged fossa; grade III= localized sellar
destruction; grade IV: diffuse destruction. Only grade III and IV tumors are considered invasive. Lower panel depicts a classification of the suprasellar extension
of an adenoma which may be symmetrical or asymmetrical: grade A= suprasellar cistern only; grade B= recess of the third ventricle; grade C= whole anterior
third ventricle; grade D= intracranial extradural; grade E= extracranial extradural (cavernous sinus). According to Knosp’s classification, Grade 0= the adenoma
does not pass the tangent of the medial aspects of the internal carotid artery (ICA); grade I= the medial tangent is passed, but the extension does not go beyond
the intercarotid line, which is the line drawn between the cross-sectional centers of the intra- and supracavernous ICA; Grade II= the tumor is extending beyond
the intercarotid line, but not beyond or tangent to the lateral aspects of the intra- and supracavernous ICA; Grade III = the tumor is extending laterally to the
lateral tangent of the intra- and supracavernous ICA; Grade IV= total encasement of the intracavernous carotid artery. Adapted from references 50 and 51.
sstr1 Agg sstr1 Non Agg sstr2 Agg sstr2 Non Agg sstr3 Agg sstr3 Non Agg sstr5 Agg sstr5 Non Agg
0
2
4
6
8
re
la
tiv
e 
ex
pr
es
si
on
co
pi
es
/b
ac
t
A
mTOR Agg mTOR Non Agg 4eBP1 Agg 4eBP1 Non Agg p70S6K Agg p70S6K Non Agg
0.0
0.2
0.4
0.6
0.8
1.0
2
4
6
8
10
re
la
tiv
e 
ex
pr
es
si
on
co
pi
es
/b
ac
t
C
Figure 2: Characterization of SSTRs, IGF1R, IRA, IRB and mTOR pathway components in human somatotroph tumors. RT-qPCR
analysis revealed that non-aggressive somatotroph tumor cells expressed slightly but non significantly higher levels of SSTRs
(Panel A) and IGF1R (Panel B) compared with aggressive somatotroph tumor cells. No significant difference in mTOR components
expression has been found between the two groups of somatotroph tumors (Panel C).
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Figure 3: Effects of PAS, EVE and PAS+EVE on SSTR gene transcription regulation in non-aggressive (Panel A) and aggressive
(Panel B) somatotroph tumors. PAS+EVE did not induce gene trascription regulation after 1h of treatment, although a trend in
increasing SSTR expression has been observed in non-aggressive somatotroph tumors (Panel A).
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Figure 4: Effects of different treatments on cell proliferation. In non-aggressive somatotroph tumors, only PAS 10-8M+EVE 10-7M
significantly reduced cell proliferation by 30%, whereas thee same drugs used alone did not significantly change cell proliferation at
tested doses (Panel A). OCT, both used alone and in combination with EVE, did not significantly change cell proliferation at tested
doses (Panel B). In 5 aggressive somatotroph tumors, neither PAS, EVE, nor PAS+EVE significanty inhibited cell proliferation at
tested doses (Panel C). In 2 non-aggressive somatotroph tumors and in 1 aggressive somatotroph tumor TMZ did not significantly
change cell proliferation at tested doses (Panel D).
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Figure 5: Effects of different treatments on GH secretion. In 5 non-aggressive somatostroph tumors, as compared to the control
PAS, EVE and PAS+EVE significantly reduced GH secretion by 23,73% (p<0.01), 21% (p<0.05) and 28,96 % (p<0.001),
respectively (Panel A). In 2 non-aggressive somatotroph tumors OCT alone or combined with EVE did not significantly reduce GH
secretion (Panel B). In 5 aggressive somatotroph tumors, PAS induced the significant GH secretion inhibition when used alone
(27,28%, p<0.01) and combined with EVE (37%, p<0.0001 vs control, p<0.001 vs EVE alone) (Panel C). In non-aggressive
somatotroph tumors TMZ did not significantly reduce GH secretion, and in aggressive somatotroph tumors it increased GH
secretion (p<0.01) probably due GH excretion most likely because of its cytotoxic effect (Panel D).
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Figure 6: Mortality in the whole cohort of patients with pituitary aggressive tumors and carcinomas. Causes of death included tumor
progression (TP) in 10 (45.4%), cerebrovascular accidents (CVA) in 8 (36.4%), heart stroke (HS) in 3 (13.6%) and other
malignancy in 1 (4.5%).
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Figure 7: Distribution of pituitary tumor histotype. NFA= 27.6%; GH-secreting tumors= 21.3%; GH and PRL-cosecreting tumors= 7.7%; PRL-
secreting tumors= 20.8%; ACTH-secreting pituitary tumors= 9%; craniopharyngiomas= 7.4%; FSH/LH-secreting pituitary tumors= 5.8%.
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Figure 8: Comparison of non-atypical non-
malignant tumors versus atypical tumors and
carcinomas. Rate of tumor growth (p=0.003),
disease recurrence (p=0.05), and laterosellar
extension was significantly higher in patients with
atypical tumors and carcinomas as compared to
those with non-atypical non-malignant tumors.
Invasion of cavernus sinus, third ventricle and
sellar floor, and suprasellar extension were
similarly reported in both groups of patients.
